Previous 10 | Next 10 |
REDWOOD CITY, Calif., Nov. 10, 2020 (GLOBE NEWSWIRE) -- Pulmonx Corporation (Nasdaq: LUNG) (“Pulmonx”), a commercial-stage medical technology company that provides minimally invasive treatment for patients with severe emphysema, a form of COPD, today reported financial results...
REDWOOD CITY, Calif., Nov. 03, 2020 (GLOBE NEWSWIRE) -- Pulmonx Corporation (Nasdaq: LUNG) (“Pulmonx”) today announced the company will be participating in two upcoming virtual investor conferences. Pulmonx management is scheduled to present at the Stifel 2020 Virtual He...
Health Care Service Corp. which operaties Blue Cross and Blue Shield plans in Illinois, Montana, New Mexico, Oklahoma and Texas, started covering Pulmonx's ([[LUNG]] +2.5%) Zephyr Endobronchial Valve for the treatment of severe emphysema on November 1. The organization is the fifth largest he...
REDWOOD CITY, Calif., Nov. 02, 2020 (GLOBE NEWSWIRE) -- Pulmonx Corporation (NASDAQ: LUNG) today announced that Health Care Service Corporation (HCSC) has issued a positive coverage policy for the Zephyr® Endobronchial Valve (Zephyr Valve) for the treatment of severe emphysema, a form ...
REDWOOD CITY, Calif., Oct. 22, 2020 (GLOBE NEWSWIRE) -- Pulmonx Corporation (Nasdaq: LUNG) (“Pulmonx”), a global leader in minimally invasive treatments for lung disease, today announced that it will release financial results for the third quarter of 2020 after the close of tr...
A total of 29 companies entered the public market this past week, the most ever in a single week. The week's 11 IPOs were joined by 15 SPACs and three direct listings. Notable new IPO filings included TPG-backed antivirus provider McAfee, Vista Equity's IT software provider Datto ...
REDWOOD CITY, Calif., Oct. 05, 2020 (GLOBE NEWSWIRE) -- Pulmonx Corporation (Nasdaq: LUNG) (“Pulmonx”), a commercial-stage medical technology company that provides a minimally invasive treatment for patients with severe emphysema, today announced the closing of its initial pub...
Pulmonx is an interesting company which has seen a very successful public offering. The company has an interesting approved product, and while it is showing growth, I am not yet impressed with the recent revenue numbers. Preliminary third-quarter procedure numbers look promising, ...
REDWOOD CITY, Calif., Sept. 30, 2020 (GLOBE NEWSWIRE) -- Pulmonx Corporation (“Pulmonx”) today announced the pricing of its upsized initial public offering of 10,000,000 shares of its common stock at a price of $19.00 per share, for gross proceeds of $190,000,000 mi...
Pulmonx (NASDAQ: LUNG ) has filed a preliminary prospectus for an $86M IPO. More news on: ProLung, Inc., Healthcare stocks news, IPO News, , Read more ...
News, Short Squeeze, Breakout and More Instantly...
2024-07-12 22:40:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...
REDWOOD CITY, Calif., July 10, 2024 (GLOBE NEWSWIRE) -- Pulmonx Corporation (Nasdaq: LUNG) (“Pulmonx”), a global leader in minimally invasive treatments for lung disease, today announced that it will release financial results for the second quarter of 2024 after the close of trading...
2024-06-23 01:22:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...